NRI Nuvo Reserch Q1 2012 Result

Yet this company had dreamed all the elements before it in order to advance its growth. However with the disappointing result of anonce and with a product that has been Temporarily rejected by the FDA, I believe that shareholders have been had by management. society increased revenues from 3.8 to 6.2 million. That it will be expected as sales of Pensaid increased. The problem with that is operating expenses. $ 2 million for expenses of sales for a company with a turnover of about 15 million per year -20,000,000. Without counting the bonuses and high salaries of dirigeants.I think this company is a joke for shareholders.

NRI.to FDA decision

Against all odds, yesterday was the date that many of us expected, the date that the FDA makes are Pliaglis verdict on the product. The company Nuvo Researchannounced that the datede césision was April 16, 2012 but no news came out.Does he need fear nothing appeared in the news, I think not. I think the decision will be revealed shortly. The company has no interest in hiding the FDA decision.However, this can be frustrating is that the company announced that the date wasApril 16 and several people looked impacience decision. The company could haveéemttre a statement saying the decision would be made soon instead of waiting for people who awaited the decision.

NRI.to - TO WATCH

Monday, we will know the FDA's decision regarding the marketing of Piaglis the United States. This decision should affect the stock price that has stabilized at a price of $ 0.13 for some days. The company is well positioned to see its share price rise with the recent news made ​​Thursday by the directions, which shows a large increase in sales due to the problem of pensaid voltaren. Moreover, with a positive decision from the FDA position and future financial results of the first quarter due out around May or June, the company is well positioned to me that one way for hisshare price continue to grow.

NRI.TO Nuvo Research inc.

Since two month, NRI shares on toronto market (Nuvo Research) have really progress. 2012 will be a great year for this company. After trade to 0,05 $, the shares are now to 0,125 $. more than 100 % of profit. Reason of this progression is the voltaren problem with her gel. NRI have profit of thi problem of increase her sales. In april 16, the FDA will show if the pensaid will be aprouved. To may month, the company will show the result of the first quarter of 2012. Results must be the best result of the society because in the report of the last quarter 2011, the company show a great increase in sales because voltaren problem. 2 Greats news should do increase the shares of the society and with the great numbers of insider transaction, they are not douth than the 2 first quarter of the company will be good.


Give me your opinion.